id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2007-D-0369-0478,FDA,FDA-2007-D-0369,Product-Specific Guidance for Cocaine Hydrochloride; Nasal Solution; New Draft Guidance for Industry; Availability,Notice,Notice of Availability,2019-12-16T05:00:00Z,2019,12,2019-12-16T05:00:00Z,2020-02-15T04:59:59Z,2020-02-13T03:46:02Z,2019-26971,0,0,0900006484212850
FDA-2007-D-0369-0476,FDA,FDA-2007-D-0369,Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,Notice,Notice of Availability,2019-11-22T05:00:00Z,2019,11,2019-11-22T05:00:00Z,2020-01-22T04:59:59Z,2020-02-28T02:02:42Z,2019-25326,0,0,0900006484197f8c
FDA-2007-D-0369-0473,FDA,FDA-2007-D-0369,Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,Notice,Notice of Availability,2019-09-17T04:00:00Z,2019,9,2019-09-17T04:00:00Z,2019-11-19T04:59:59Z,2019-10-24T01:01:31Z,2019-20108,0,0,0900006483f85f87
FDA-2007-D-0369-0471,FDA,FDA-2007-D-0369,"Product-Specific  Guidances; Draft and Revised Draft Guidance for Industry;
Availability",Notice,Notice of Availability,2019-05-16T04:00:00Z,2019,5,2019-05-16T04:00:00Z,2019-07-16T03:59:59Z,2019-05-16T12:59:56Z,2019-10165,0,0,0900006483c88ec8
FDA-2007-D-0369-0472,FDA,FDA-2007-D-0369,Draft Guidance on Rifaximin,Other,Guidance,2019-05-16T04:00:00Z,2019,5,2019-05-16T04:00:00Z,,2024-11-12T23:00:59Z,,1,0,0900006483c89d9b
FDA-2007-D-0369-0467,FDA,FDA-2007-D-0369,Product-Specific Guidances; Draft and Revised Draft Guidances for Industry; Availability,Notice,Notice of Availability,2019-02-25T05:00:00Z,2019,2,2019-02-25T05:00:00Z,2019-04-27T03:59:59Z,2019-04-27T01:03:41Z,2019-03129,0,0,0900006483aa2c9e